172 related articles for article (PubMed ID: 16000949)
21. Dendritic cells are targets for human invariant Valpha24+ natural killer T-cell cytotoxic activity: an important immune regulatory function.
Nicol A; Nieda M; Koezuka Y; Porcelli S; Suzuki K; Tadokoro K; Durrant S; Juji T
Exp Hematol; 2000 Mar; 28(3):276-82. PubMed ID: 10720692
[TBL] [Abstract][Full Text] [Related]
22. Human peripheral blood Valpha24+ Vbeta11+ NKT cells expand following administration of alpha-galactosylceramide-pulsed dendritic cells.
Okai M; Nieda M; Tazbirkova A; Horley D; Kikuchi A; Durrant S; Takahashi T; Boyd A; Abraham R; Yagita H; Juji T; Nicol A
Vox Sang; 2002 Oct; 83(3):250-3. PubMed ID: 12366768
[TBL] [Abstract][Full Text] [Related]
23. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.
Hameg A; Apostolou I; Leite-De-Moraes M; Gombert JM; Garcia C; Koezuka Y; Bach JF; Herbelin A
J Immunol; 2000 Nov; 165(9):4917-26. PubMed ID: 11046017
[TBL] [Abstract][Full Text] [Related]
24. Phenotypic and functional characterization of long-term cultured rhesus macaque spleen-derived NKT cells.
Gansuvd B; Hubbard WJ; Hutchings A; Thomas FT; Goodwin J; Wilson SB; Exley MA; Thomas JM
J Immunol; 2003 Sep; 171(6):2904-11. PubMed ID: 12960313
[TBL] [Abstract][Full Text] [Related]
25. Synergistic effect of KRN7000 with interleukin-15, -7, and -2 on the expansion of human V alpha 24+V beta 11+ T cells in vitro.
Nishi N; van der Vliet HJ; Koezuka Y; von Blomberg BM; Scheper RJ; Pinedo HM; Giaccone G
Hum Immunol; 2000 Apr; 61(4):357-65. PubMed ID: 10715513
[TBL] [Abstract][Full Text] [Related]
26. Detection and activation of human Valpha24+ natural killer T cells using alpha-galactosyl ceramide-pulsed dendritic cells.
Fujii S; Shimizu K; Steinman RM; Dhodapkar MV
J Immunol Methods; 2003 Jan; 272(1-2):147-59. PubMed ID: 12505720
[TBL] [Abstract][Full Text] [Related]
27. The effects of alphaGalCer-induced TCRValpha24 Vbeta11(+) natural killer T cells on NK cell cytotoxicity in umbilical cord blood.
Ueda Y; Hagihara M; Gansuvd B; Yu Y; Masui A; Okamoto A; Higuchi A; Tazume K; Kato S; Hotta T
Cancer Immunol Immunother; 2003 Oct; 52(10):625-31. PubMed ID: 12802518
[TBL] [Abstract][Full Text] [Related]
28. Phenotypical and functional alterations during the expansion phase of invariant Valpha14 natural killer T (Valpha14i NKT) cells in mice primed with alpha-galactosylceramide.
Ikarashi Y; Iizuka A; Koshidaka Y; Heike Y; Takaue Y; Yoshida M; Kronenberg M; Wakasugi H
Immunology; 2005 Sep; 116(1):30-7. PubMed ID: 16108815
[TBL] [Abstract][Full Text] [Related]
29. Age-associated augmentation of the synthetic ligand- mediated function of mouse NK1.1 ag(+) T cells: their cytokine production and hepatotoxicity in vivo and in vitro.
Inui T; Nakagawa R; Ohkura S; Habu Y; Koike Y; Motoki K; Kuranaga N; Fukasawa M; Shinomiya N; Seki S
J Immunol; 2002 Dec; 169(11):6127-32. PubMed ID: 12444115
[TBL] [Abstract][Full Text] [Related]
30. Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection.
van der Vliet HJ; von Blomberg BM; Hazenberg MD; Nishi N; Otto SA; van Benthem BH; Prins M; Claessen FA; van den Eertwegh AJ; Giaccone G; Miedema F; Scheper RJ; Pinedo HM
J Immunol; 2002 Feb; 168(3):1490-5. PubMed ID: 11801694
[TBL] [Abstract][Full Text] [Related]
31. Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs.
Osada T; Morse MA; Lyerly HK; Clay TM
Int Immunol; 2005 Sep; 17(9):1143-55. PubMed ID: 16027139
[TBL] [Abstract][Full Text] [Related]
32. A novel recognition motif of human NKT antigen receptor for a glycolipid ligand.
Kawano T; Tanaka Y; Shimizu E; Kaneko Y; Kamata N; Sato H; Osada H; Sekiya S; Nakayama T; Taniguchi M
Int Immunol; 1999 Jun; 11(6):881-7. PubMed ID: 10360961
[TBL] [Abstract][Full Text] [Related]
33. Killing activity of human umbilical cord blood-derived TCRValpha24(+) NKT cells against normal and malignant hematological cells in vitro: a comparative study with NK cells or OKT3 activated T lymphocytes or with adult peripheral blood NKT cells.
Hagihara M; Gansuvd B; Ueda Y; Tsuchiya T; Masui A; Tazume K; Inoue H; Kato S; Hotta T
Cancer Immunol Immunother; 2002 Mar; 51(1):1-8. PubMed ID: 11845254
[TBL] [Abstract][Full Text] [Related]
34. Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load.
Molling JW; Kölgen W; van der Vliet HJ; Boomsma MF; Kruizenga H; Smorenburg CH; Molenkamp BG; Langendijk JA; Leemans CR; von Blomberg BM; Scheper RJ; van den Eertwegh AJ
Int J Cancer; 2005 Aug; 116(1):87-93. PubMed ID: 15756674
[TBL] [Abstract][Full Text] [Related]
35. Expansion of invariant natural killer T cells from systemic lupus erythematosus patients by alpha-Galactosylceramide and IL-15.
Hsu CY; Chueh YS; Kuo ML; Lee PT; Hsiao HS; Huang JL; Lin SJ
PLoS One; 2021; 16(12):e0261727. PubMed ID: 34936686
[TBL] [Abstract][Full Text] [Related]
36. NKT cells act as regulatory cells rather than killer cells during activation of NK cell-mediated cytotoxicity by alpha-galactosylceramide in vivo.
Chamoto K; Takeshima T; Kosaka A; Tsuji T; Matsuzaki J; Togashi Y; Ikeda H; Nishimura T
Immunol Lett; 2004 Aug; 95(1):5-11. PubMed ID: 15325792
[TBL] [Abstract][Full Text] [Related]
37. Discrepancies of NKT cells expression in peripheral blood and in cerebrospinal fluid from Behçet's disease.
Hamzaoui K; Kamoun M; Houman H; Hentati F; Hamza M; Ayed K; Hamzaoui A
J Neuroimmunol; 2006 Jun; 175(1-2):160-8. PubMed ID: 16624421
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity.
Nieda M; Okai M; Tazbirkova A; Lin H; Yamaura A; Ide K; Abraham R; Juji T; Macfarlane DJ; Nicol AJ
Blood; 2004 Jan; 103(2):383-9. PubMed ID: 14512316
[TBL] [Abstract][Full Text] [Related]
39. Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma.
Renukaradhya GJ; Khan MA; Vieira M; Du W; Gervay-Hague J; Brutkiewicz RR
Blood; 2008 Jun; 111(12):5637-45. PubMed ID: 18417738
[TBL] [Abstract][Full Text] [Related]
40. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
